Role of P-glycoprotein in the hepatic metabolism of tacrolimus

References

• Achira M, Suzuki H, Ito K, Sugiyama Y. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. 1999, AAPS PharmScience 1:E18
   Google Scholar
• Annaert PP, Turncliff RZ, Booth CL, Thakker DR, Brouwer KL. P-glycoprotein-mediated in vitro biliary excretion in sandwich-cultured rat hepatocytes. Drug Metabolism and Disposition 2001; 29: 1277–1283
   PubMed Web of Science ®Google Scholar
• Booth CL, Brouwer KR, Brouwer KL. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. Cancer Research 1998; 58: 3641–3648
   PubMed Web of Science ®Google Scholar
• Brouwer KL, Thurman RG. Isolated perfused liver. Pharmacology and Biotechnology 1996; 8: 161–192
   PubMedGoogle Scholar
• Chiou WL, Chung SM, Wu TC. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Pharmacology Research 2000a; 17: 205–208
   PubMed Web of Science ®Google Scholar
• Chiou WL, Chung SM, Wu TC. Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharmacology Research 2000b; 17: 903–905
   PubMed Web of Science ®Google Scholar
• Chiou WL, Chung SM, Wu TC, Ma C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. International Journal of Clinical Pharmacology and Therapy 2001; 39: 93–101
   PubMed Web of Science ®Google Scholar
• Christians U, Jacobsen W, Serkova N, Benet LZ, Vidal C, Sewing KF, Manns MP, Kirchner GI. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: Immunosuppressants. Journal of Chromatography B: Biomedical and Science Applications 2000; 748: 41–53
   PubMed Web of Science ®Google Scholar
• Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clinical and Pharmacology Therapy 2002; 72: 474–489
   PubMed Web of Science ®Google Scholar
• Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metabolism and Disposition 1999; 27: 866–871
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharmacology Research 1993; 10: 1093–1095
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Perrier D. Pharmacokinetics. M. Dekker, New York, NY 1982; 8: 494
   Google Scholar
• Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Molecular Pharmacology 2001; 59: 806–813
   PubMed Web of Science ®Google Scholar
• Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Research 1993; 53: 4595–4602
   PubMed Web of Science ®Google Scholar
• Jeong HY, Chiou WL. Rapid intestinal absorption mechanism of tacrolimus, a large molecule: Role of p-glycoprotein and lack of active uptake. 2003, AAPS Pharm Sci 5:W436
   Google Scholar
• Lan LB, Dalton JT, Schuetz EG. Mdr1 limits CYP3A metabolism in vivo. Molecular Pharmacology 2000; 58: 863–869
   PubMed Web of Science ®Google Scholar
• Lee HJ, Chiou WL. Erythrocytes as barriers for drug elimination in the isolated rat liver. I. Doxorubicin. Pharmacology Research 1989; 6: 833–839
   PubMed Web of Science ®Google Scholar
• Lin JH, Yamazaki M. Role of p-glycoprotein in pharmacokinetics: clinical implications. Clinical Pharmacokinetics 2003; 42: 59–98
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, Van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proceedings of the National Academy of Sciences, USA 1997; 94: 2031–2035
   Google Scholar
• Takada K, Usuda H, Oh-Hashi M. Distribution kinetics of FK-506, a novel immunosuppressant, after intravenous administration to rats in comparison with cyclosporin A. Biopharmacology and Drug Disposition 1992; 13: 345–355
   PubMedGoogle Scholar
• Thompson JA, Malkinson AM, Wand MD, Mastovich SL, Mead EW, Schullek KM, Laudenschlager WG. Oxidative metabolism of butylated hydroxytoluene by hepatic and pulmonary microsomes from rats and mice. Drug Metabolism and Disposition 1987; 15: 833–840
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T. Clinical pharmacokinetics of tacrolimus. Clinical Pharmacokinetics 1995; 29: 404–430
   PubMed Web of Science ®Google Scholar
• Vincent SH, Karanam BV, Painter SK, Chiu SH. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: Identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Archives in Biochemistry and Biophysics 1992; 294: 454–460
   PubMed Web of Science ®Google Scholar
• Ward KW, Azzarano LM. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey. Journal of Pharmacology and Experimental Therapy 2004; 310: 703–709
   PubMed Web of Science ®Google Scholar
• Watanabe T, Miyauchi S, Sawada Y, Iga T, Hanano M, Inaba M, Sugiyama Y. Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver. Possible roles of P-glycoprotein in biliary excretion of vincristine. Journal of Hepatology 1992; 16: 77–88
   PubMed Web of Science ®Google Scholar
• Yokogawa K, Takahashi M, Tamai I, Konishi H, Nomura M, Moritani S, Miyamoto K, Tsuji A. P-glycoprotein-dependent disposition kinetics of tacrolimus: Studies in mdr1a knockout mice. Pharmacology Research 1999; 16: 1213–1218
   PubMed Web of Science ®Google Scholar